Established Knowledge
The treatment of headaches begins with making a diagnosis, explaining it to the patient, and developing a treatment plan taking into account the severity and frequency of the headache.
Headache is most often a very painful and bothersome disorder in which drug treatment is needed acutely. In addition, when migraine, cluster headache and tension-type headache are occurring frequently, preventive daily intake of a drug may be needed.
Acute drugs for migraine are specific drugs, such as triptans and ergot alkaloids, and non-specific drugs such as paracetamol, aspirin and other NSAIDs. For acute treatment of cluster headache only quickly absorbed triptans are effective. Tension-type headaches are treated acutely with analgesics.
Triptans are not effective in episodic tension-type headache (Brennum et al. 1996) .
For prophylaxis of migraine several types of drugs can be used, including β-blockers, anti-epileptics and calcium channel blockers ). Only one drug, methysergide, was designed for migraine prophylaxis and it is rarely used because of risk of severe side effects. The prophylactic drug of first choice in cluster headache is verapamil. In frequent and chronic tension-type headache tricyclic antidepressant drugs are used.
Worldwide the use of drugs is heavily dependent on the WHO's list of essential drugs and this list will be discussed. Cost is still an important factor, especially with the triptans for which the patent has not expired. With all acute drugs for headache there is the risk for overuse with resulting daily headache (see Chapter 47). Headache disorders are often chronic disorders wherefore tolerability and safety are important issues. RCTs provided evidence that effervescent aspirin 1,000 mg is as effective as sumatriptan 50 mg for the acute treatment of migraine attacks, and that both are superior to placebo (Lampl et al. 2007 ).
WHO's essential medicines list for migraine
This is illustrated by the meta-analysis results for pain relief at 2 hours, defined as a decrease in headache from moderate or severe to none or mild after 2 hours, amounting to 52 % (95% CI: 47 -57%) for effervescent aspirin 1,000 mg which is quite comparable to sumatriptan 50 mg (47%, 95%
CI: 40-52%), and both are significantly superior to placebo (34%, 95% CI: 29-39%). These results seemingly demonstrate that the two groups of drugs, triptans and NSAIDs, are equivalent in migraine treatment (Lampl et al. 2007 ). Comparisons of oral triptans with other classes of acute treatments are few, and in general differences between active treatments on the primary endpoints were not dramatic (Lipton et al. 2004) . Nevertheless these data have been questioned as there is a discrepancy with experience in clinical practice (Lipton et al. 2004) . We are as clinicians confronted every day with migraine patients that do not respond to analgesics or NSAIDs. There is thus the need for more migraine-specific drugs such as triptans or ergot alkaloids. Regardless of this a drug like effervescent aspirin should be the drug of first choice in migraine, but triptans or ergot alkaloids should be available for those patients unresponsive to aspirin. For most migraine sufferers requiring a specific anti-migraine treatment, a triptan is generally a better option from both an clinical expertise with the best available external clinical evidence from systematic research" (Sackett et al. 1996) . Evidence-based medicine is more than just meta-analyses of drugs and 6 procedures. WHO seemingly does not understand the second part of evidence-based medicine: the integration of individual clinical expertise into the decision. What do you do when you have a migraine patient who has unsuccessfully tried aspirin for three migraine attacks. As shown in the meta-analysis even with the optimal aspirin, effervescent aspirin 1,000 mg, 50% of the patients don't respond with headache relief and 70% are not pain free after 2 hours (Lampl et al. 2007 ).
Most patients with headache worldwide self-medicate for migraine, using aspirin and paracetamol 
Benefit/tolerability ratio for specific migraine drugs
The best available evidence comes from systematic reviews (or meta-analyses) of RCTs. In migraine there are several meta-analyses, mostly on triptans Ferrari et al. 2001; McCrory and Gray 2003; Pascual 2004; Saxena and Tfelt-Hansen 2006) . The efficacy is most often well described in RCTs whereas adverse events are currently reported in different ways. This makes comparison of tolerability in systematic reviews problematic. A practical example on the choice between the two administration forms of sumatriptan, oral and subcutaneous, plus the choice in cluster headache, is given in Table 2 . As is shown subcutaneous sumatriptan 6 mg is both more effective and causes more adverse events than the oral form of sumatriptan 100 mg. Subcutaneous sumatriptan is also more quickly effective (relevant effect after 20 min) than oral sumatriptan (relevant effect after 60 min) (Saxena and Tfelt-Hansen 2006) . Apparently, the simple benefit/tolerability is better for oral sumatriptan (32%/16% = 2) than subcutaneous sumatriptan (51%/33% = 1.5) but clinical treatment is not that simple. Most patients prefer the oral route of 7 administration. The price of subcutaneous sumatriptan 6 mg is very high, 37 € versus 1 € for sumatriptan 50 mg (current prices in Denmark). In cluster headache the situation is different. The attack is very severe but short-lasting. So the treatment should work quickly with a high response rate. Even if intranasal sumatriptan 20 mg and zolmitriptan 5 mg are statistically superior to placebo, it is only subcutaneous sumatriptan 6 mg which has an early clinically relevant effect (Table 2 ).
In prophylaxis of migraine adverse events are in our experience the most frequent reasons for stopping the treatment. One should be aware of the fact that drugs results in very variable plasma levels, often 5 to 10 fold differences among subjects. In addition, there is a pharmacodynamic
variability (Tfelt-Hansen and Edvinsson 2007). This variability is especially important in migraine
prophylaxis. The dictum should be "start low, go slow". Usually we start out with ¼ to ½ of the dose used in RCTs and then slowly over weeks to months increase the dose depending on efficacy and tolerability. Such a tailoring of the drug to the individual patients can usually not be done in
RCTs.
These examples hopefully illustrate that the benefit/tolerability ratio is content dependent and it is the responsibility of the physician to try optimize the treatment of the individual patient. Table 2 .
Data from randomised clinical trials (RCTs) Data not evident from RCTs and personal clinical experiences Sumatriptan 100 mg is superior to placebo in RCTs with a therapeutic gain (TG) of 32% . There are 16% (95% CI: 13-19%) more adverse events after sumatriptan than after placebo. Sumatriptan 100 mg begins to have a clinically relevant effect after 60 min with a maximum after 120 min. Sumatriptan 6 mg subcutaneous (SC) has a TG of 51%. There are 33% (95% CI: 29-37%) more adverse events after sumatriptan 6 mg SC than after placebo. Sumatriptan 6 mg SC begins to have a clinically relevant effect after 20 min with a maximum effect after 60 min.
The plasma level of sumatriptan varies considerably ( 4-10 fold) after oral administration. Most patients prefer the oral route of administration. Sumatriptan 6 mg SC is very costly (37 €) versus sumatriptan tablets 50 mg (1 €).
Migraine Efficacy/tolerability ratio: Both oral (TG: 32%) and SC sumatriptan (TG: 51%) are effective. Sumatriptan 6 mg SC causes more adverse events than oral sumatriptan (33% versus 16% more than placebo).
Because of the more frequent adverse events after sumatriptan 6 mg SC the oral form has clinically the best efficacy/tolerability ratio in migraine. The oral form is also much cheaper (1 € versus 30 €). If very quick effect is needed sumatriptan 6 mg SC is better than the oral form. Cluster headache Sumatriptan 6 mg SC is effective in cluster headache: within 15 min 74% of sumatriptan treated attacks responded (no or mild headache) versus 26% of placebo treated attacks. After nasal sumatriptan 20 mg 57% responded after 30 min versus 26% after placebo. Nasal zolmitriptan 5 mg resulted in 48% response after 30 min versus 19% response after placebo.
Given the short duration and severity of attacks, rapidity of action is a crucial factor. Sumatriptan 6 mg SC has quicker onset of action and is more effective than the nasal triptans. SC sumatriptan is generally the drug of first choice.
Legend Table 2 : A practical example of the choice between two administration forms of triptans based on the benefit/risk ratio Barriers to optimal drug choice in the treatment of headache disorders Underdiagnosis and diagnostic delay have been well documented in a number of headache disorders, including common syndromes such as migraine and cluster headache Bahra and Goadsby 2004) . Even when a correct diagnosis has been made, undertreatment and mismanagement have been observed despite the existence of guidelines for clinical practice (May et al. 2006; Steiner et al. 2007; Evers et al. 2009 ). Patients may receive acute treatment, but no prevention (when indicated) and vice versa. Ineffective acute drugs or prophylactic drugs may have been proposed to patients. The proportion of IHS-defined migraineurs using only over-the-counter medications to treat their headaches was 57% in the American Migraine Study II ). There was a clear underuse of migraine prevention in the American Migraine Prevalence and Prevention study (Diamond et al. 2007) . A significant fraction of cluster headache patients never have had access to SC sumatriptan or high-flow oxygen, both first line acute treatments according to current recommendations (May et al. 2006; Van Alboom et al. 2009 ). Cluster headache patients may receive ineffective prophylactic drugs such as propranolol, carbamazepine or amitriptyline (Van Alboom et al. 2009 ). Medication-overuse headache is a major public health concern and affects 0.7% to 1.7% of the population (Evers and Marziniak 2010) . Medication-overuse headache has been described in a variety of headache disorders including tension-type headache, migraine and cluster headache (Diener and Limmroth 2004; Paemeleire et al. 2006) . In principle, all acute drugs for the treatment of headache could cause MOH (Evers and Marziniak 2010) .
Appropriate treatment may have been advised, but patients may lapse from care (Edmeads 2006) . It is however important that resources are available to guarantee adequate follow-up of patients to ensure that optimum treatment has been established ). Stepped care guidelines 10 are available in acute migraine treatment ), and we have made the case for triptans in non-responders to NSAIDs in acute migraine.
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